Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Globe Newswire•04/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.